Study Shows Peritoneal Mesothelioma Surgery Underutilized

August 13, 2020 By Melissa Soria

The continued underutilization of aggressive surgery for peritoneal mesothelioma is shortening survival time dramatically for patients who could qualify for, and benefit from, the highly effective procedure. Only a third of those diagnosed with peritoneal mesothelioma are undergoing potentially curative cytoreductive mesothelioma surgery, according to a comprehensive study of the National Cancer Database by researchers at…

Chicago Unions Stepping Up During COVID-19 Pandemic

April 3, 2020 By Melissa Soria

Chicago unions are stepping up during this pandemic to assist in any way they can. Teamsters Local 703 workers at Chicago’s International Produce Market have been slammed since the COVID-19 pandemic hit, but they’ve been working overtime to keep Chicagoland’s grocery stores stocked with fresh produce. “Basically, we’re on the front lines,” Ken Johnson, member…

Asbestos Safety

May 16, 2019 By swarren

Asbestos, a group of naturally occurring minerals, is widely known as a hazardous substance. Because it is so dangerous, asbestos safety is crucial. Thanks to the substance’s natural resistance to heat and corrosion, it has been popular in numerous industries for centuries. The so-called “miracle mineral” rose in popularity in the 1900s. These qualities made…

Asbestos Law in the United States

April 11, 2019 By swarren

Asbestos law has a long history in the United States and worldwide. Litigation related to asbestos exposure has been happening for decades across the world. In fact, asbestos litigation has even been called the longest-running mass tort in United States history. A tort is a legal process that alleges wrongdoing against a victim, or plaintiff,…

Nicholas Vogelzang Presents at Perrin Conferences

March 21, 2019 By Nicholas Vogelzang

I was recently given the opportunity to speak at the Perrin Cutting-Edge Issues in Asbestos Litigation Conference in Beverly Hills, California. This conference is unique in that, unlike most conferences for lawyers involved in a particular area of litigation, it brings together lawyers representing both sides, in addition to insurance carriers that ultimately pay the…

Vogelzang Law Settles Two Mesothelioma Cases for $2 Million

February 19, 2019 By swarren

Chicago, IL (February 19, 2019) — The new year is off to an exciting start for the Vogelzang Law team and its clients, as the firm secured two major settlements totaling over $2,000,000 within a week. After much hard work, the firm successfully settled two cases, offering closure to the families after facing a challenging…

Vogelzang Law Settles Two Mesothelioma Cases for $3 Million

August 1, 2018 By swarren

Chicago, IL (August 1, 2018) — July came to an exciting close for Vogelzang Law, as the firm achieved settlements in two major cases within a week. In a compelling take-home asbestos case, attorney Wyatt Berkover represented a Scottish immigrant and longtime Chicagoan diagnosed with mesothelioma in 2017. The firm also saw victory for a…

Vogelzang Law News

Environmental Protection Agency (EPA) lists asbestos as one of the 10 high-risk chemicals

December 19, 2016 By Vogelzang Law Webmaster

On December 1, 2016 the Environmental Protection Agency (EPA) listed asbestos as one of the 10 high-risk chemicals evaluated and regulated under the Lautenberg Act.  What this means is that the EPA must release a scoping document within six months which includes the hazards, exposures, conditions of use and vulnerable populations the agency plans to…

Vogelzang Law News

UNIVERSITY OF CHICAGO MESOTHELIOMA DRUG TRIALS NEW HOPE FOR MESOTHELIOMA PATIENTS

July 29, 2016 By Vogelzang Law Webmaster

A clinical study of malignant pleural mesothelioma patients treated with investigational cancer vaccine CRS-207 at University of Chicago Medical Center, UCSF’s cancer center, the Moffitt Cancer Center in Tampa, the Abramson Cancer Center in Philadelphia and the National Cancer Institutein Bethesda, Maryland has shown promising results in shrinking tumors. CRS-207 caused tumor shrinkage in 85% of…